Investors were none too pleased with Charles River Laboratories' outlook for 2013, as the CRO fell as much as 8% after projecting growth below analyst estimates.
Catalent has signed a deal to provide biosimilar cell lines to Japan's UMN Pharma, a development and manufacturing agreement designed to jump-start the CMO's presence on the Asian market.
AstraZeneca is reaching out to Quintiles as it gathers data on AZD6765, part of a newfangled class of depression drugs that promises to beat what's on the market.
Perceptive Informatics, Parexel International's eClinical unit, has opened a customer care office in Shanghai to assist its digital trial management clients there and help drive adoption of its products in the country.
Swedish CRO TFS International is buying up Dimensione Ricerca, an Italian contract researcher, aiming to expand its European capabilities for cross-continent, late-stage clinical trials.
Swedish CDMO Recipharm is banking on a growing demand for analytical drug development services, planning to reconstruct its Solna, Sweden, facility to house its data-based offerings.
Covance picked up a Good Laboratory Practice Certificate for its Shanghai early development facility, a regulatory milestone the CRO says gives it a leg up on global competitors.
Alimera Sciences is facing an uphill battle getting its chronic diabetic macular edema drug on shelves in Europe, and now the company has recruited Quintiles to manage the European launch of Iluvien.
Amid budget-slashing and restructuring, AMRI has some good news to report: The CRO has re-signed with GE Healthcare to supply materials for diagnostic imaging, locking down its biggest commercial supply client through 2016.
CMO NextPharma has sold its U.S. manufacturing operation, Bioserv, to private equity player KESA Partners for an undisclosed sum, planning to focus on its core European operation.
Vaccine outfit Selecta Biosciences has signed an agreement with Sanofi to discover antigen-specific immunotherapies for food allergies, and the deal includes rights to an initial therapy with the option to develop two more.
Thanks to lax regulations and legal loopholes, Indian regulators have little control over the conduct of CROs in the country, but the government is on the path to reforms that would help rein in "fly-by-night" trial operators, officials said.
Parexel International is adding another academic partner to its list of overseas collaborators, inking a deal with the National Taiwan University Hospital to provide drug development services in the country.
The majority of Big Pharma companies use CROs to conduct clinical trials in the developing world, but very few could provide evidence that they'd ever disciplined contractors that ran afoul of ethics codes, possibly putting participants at risk, according to a study by the Access to Medicine Foundation.
CRO AMRI is closing up its R&D shop in Bothell, WA, and shipping the site's biology capabilities to its drug discovery operation in Singapore.
Big Pharma seems to be feeling the spirit of collaboration of late, and Pfizer and AstraZeneca have joined forces to launch the Néomed Institute, a nonprofit drug R&D outfit that will unite CROs, schools, biotechs and VCs to develop and commercialize new therapies.
CRO Medpace has bought MediTech Strategic Consultants, a European contract researcher that specializes in medical device R&D.
The EU is looking to liberalize its clinical trial regulations to spur drug development in the Continent, and the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) wants to hear from CROs and drugmakers on the proposed reforms.
QPS is adding 24 beds to its Phase I facility in Groningen, Netherlands, citing an increase in demand for its quick-turnaround, complex research.
China's Innovent Biologics is looking to build the largest GMP biologics plant in China, a belt currently held by WuXi PharmaTech, and the company has $25 million in new investments to get it done.